NCE-1 Intelligence & Market Opportunity

Xocova

Ensitrelvir

Antiviral

Oral Tablet

Xocova (ensitrelvir) is an oral antiviral indicated for the prevention and treatment of COVID-19 due to SARS-CoV-2 infection. Xocova selectively inhibits the 3CL protease, blocking this essential viral enzyme required for replication, helping to reduce viral load and limit disease progression.

This therapy is a significant advance in the treatment of COVID-19 with an easy-to-take oral medication for early treatment and post-exposure prophylaxis. Xocova is designed to inhibit viral replication at its source, supporting ongoing efforts to reduce the impact of COVID-19 and improve patient outcomes through effective antiviral therapy.

Approval Date

29-May-26

NCE-1 Date

29-May-30

NCE Date

29-May-31

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

100

2027

102

2028

114

2029

122

2030

130

2031

139

2032

148

Molecule profile

Details & specifications

Molecule

Ensitrelvir

Innovator

SHIONOGI

Dosage Form

Oral Tablet

Strength

125 mg

Therapeutic Category

Antiviral

Usage

To use as post-exposure prophylaxis of coronavirus disease 2019 (COVID-19) following contact with an individual who has COVID-19

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.